In addition, we observed a trend of improved recurrence-free survival in the HCC-Gao patients that did not overexpress FGFR4 protein compared to those overexpressing FGFR4 (p = 0.087; FGFR4-not-overexpressed median survival 23.2 months; FGFR4-overexpressed median survival 9.5 months) (Figure S8), although the association did not reach statistical significance and require validation in future larger-scale cohorts. Here, FGFR4 is linked to hepatocellular carcinoma.